The use of beta-adrenergic blocking drugs in patients with myocardial infarction.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000526:Alprenolol / Q000627:therapeutic use; D000787:Angina Pectoris / Q000188:drug therapy; D001262:Atenolol / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008790:Metoprolol / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000517:prevention & control; D010096:Oxprenolol / Q000627:therapeutic use; D010869:Pindolol / Q000627:therapeutic use; D011217:Practolol / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D012306:Risk; D013015:Sotalol / Q000627:therapeutic use; D013999:Timolol / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D011943:Receptors, Adrenergic, beta; D001262:Atenolol; D010096:Oxprenolol; D013999:Timolol; D000526:Alprenolol; D011433:Propranolol; D013015:Sotalol; D010869:Pindolol; D008790:Metoprolol; D011217:Practolol